This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.
Age ≥18 years old
History of myocardial infarction
Have received coronary interventional therapy
There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% )
Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
Previously received coronary artery bypass grafting
Stroke occurred within the previous 3 months
Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction < 35%
Parallel
Xuesaitong Soft Capsule
DrugEach participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.
Placebo
DrugEach participant in the placebo group will take matching placebo.
hsCRP
Changes in high-sensitivity C-reactive protein level from baseline at 12 weeks
Other inflammation indicators
Changes in levels of interleukin-6, interleukin-10, interleukin-1β, tumor necrosis factor-α from baseline at 12 weeks
IPA
Changes in level of inhibition of platelet aggregation from baseline at 12 weeks
Vascular endothelial function
Changes in intercellular adhesion molecule-1, von Willebrand factor, and endothelin-1 levels from baseline at 12 weeks
Blood lipid profiles
Changes in total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, small low-density lipoprotein cholesterol, and triglyceride levels from baseline at 12 weeks
Click on the lead sponsor to view all of their trials.
